Potential biomarkers to follow the progression and treatment response of Huntington’s disease
Open accessThe DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
Abstract
Huntington’s disease (HD) is a rare genetic disease caused by expanded polyglutamine repeats in the huntingtin protein resulting in selective neuronal loss. Although genetic testing readily identifies those who will be affected, current pharmacological treatments do not prevent or slow down disease progression. A major challenge is the slow clinical progression and the inability to biopsy the affected tissue, the brain, making it difficult to design short and effective proof of concept clinical trials to assess treatment benefit. In this study, we focus on identifying peripheral biomarkers that correlate with the progression of the disease and treatment benefit. We recently developed an inhibitor of pathological mitochondrial fragmentation, P110, to inhibit neurotoxicity in HD. Changes in levels of mitochondrial DNA (mtDNA) and inflammation markers in plasma, a product of DNA oxidation in urine, mutant huntingtin aggregates, and 4-hydroxynonenal adducts in muscle and skin tissues were all noted in HD R6/2 mice relative to wild-type mice. Importantly, P110 treatment effectively reduced the levels of these biomarkers. Finally, abnormal levels of mtDNA were also found in plasma of HD patients relative to control subjects. Therefore, we identified several potential peripheral biomarkers as candidates to assess HD progression and the benefit of intervention for future clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. Analysis of mtDNA content in brain and plasma. (A) DNA synthetized from mouse brain tissue was used in real-time PCR with mtND2 primers targeting mouse mtDNA (n = 4 mice per group). (B) mtND2 DNA content in plasma samples from mouse blood collected at the age of 13 wk were assayed by real-time PCR (n = 10 WT and n = 8 R6/2 Tg mice). Housekeeping nuclear gene, GAPDH, was used for normalization. (C) Change in mtND2 levels over time in mice. Mouse plasma samples from WT and R6/2 mice were collected every 2 wk, and mtND2 levels were determined using real-time PCR. mtND2 levels decreased over time in R6/2 mice as compared with WT mice (n = 10 WT; n = 10 R6/2 [5–11-wk-old mice]; n = 9 [13-wk-old mice]). The data are presented as mean ± SEM of 2−ΔΔCT. *, P = 0.0006; **, P = 0.0055; ***, P = 0.00017 versus WT 5 wk; #, P = 0.00085 versus WT 7 wk; ##, P = 0.004 versus WT 13 wk (unpaired Student’s t test and one-way ANOVA).](https://figures.cochat.ai/paper-figures/a8a6377d85494b5fabba696d2812f99f/potential-biomarkers-to-follow-the-progression-and-treatment-response-of-figure-1.jpg)






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition to direct neuronal toxicity, HD pathogenesis is accompanied by significant neuroinflammation [192]. Brains impacted with HD exhibit increased microglial activation and elevated pro-inflammatory cytokine levels, including IL-6 and TNF-α [193,194].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [193]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · cited 2×
“Relative changes in gene expression was calculated using the 2−ΔΔCT method (Livak and Schmittgen, 2001), where ΔΔCT = (CT,mtND2 − CT,GAP DH)treatment − (CT,mtND2 − CT,GAP DH)control.”
MethodMACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837
Adams, J. L., Dinesh, K., Xiong, M., Tarolli, C. G., Sharma, S., Sheth, N., Aranyosi, A. J., Zhu, W., Goldenthal, S., Biglan, K. M., et al. (2017) · Digital Biomarkers · doi:10.1159/000479018 · Cited by 3,171
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Shah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055
Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain
DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,439 · cited 2×
“Aggregates of mtHtt were previously reported in the brains of human HD patients (DiFiglia et al., 1997) and R6/2 mice when measured at the age of 13 wk (Guo et al., 2013).”
BackgroundHuntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,743 · cited 1×
“Progressive loss of striatal and cortical neurons mediates the cognitive and motor impairments in HD patients and in R6/2 mice (Ross and Tabrizi, 2011; Guo et al., 2013).”
BackgroundMitochondrial dynamics-fusion, fission, movement, and mitophagy-in neurodegenerative diseases
Chen, H., & Chan, D. C. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp326 · Cited by 1,458 · cited 1×
“1 C) probably reflect initially cell damage and subsequently decline in cell and/or mitochondrial number (Chen and Chan, 2009; Podlesniy et al., 2013).”
BackgroundBrowne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410514 · Cited by 885 · cited 2×
“Our data are also consistent with five of six other patient sample analyses (Browne et al., 1997; Polidori et al., 1999; Hersch et al., 2006; Chen et al., 2007; Long et al., 2012; Ciancarelli et al., 2014).”
BackgroundResultInfluentialSelective striatal neuronal loss in a YAC128 mouse model of Huntington disease
Slow, E. J. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg169 · Cited by 800 · cited 1×
“This mouse model exhibits a much slower disease progression as compared with R6/2 mice, with end stage and death occurring at about >1.5 yr (Slow et al., 2003).”
BackgroundInfluentialUrinary 8-hydroxy-2'-deoxyguanosine as a biological marker of in vivo oxidative DNA damage.
Shigenaga, M. K., Gimeno, C. J., & Ames, B. N. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.9697 · Cited by 732
Identification of Genetic Factors that Modify Clinical Onset of Huntington’s Disease
Lee, J.-M., Wheeler, V. C., Chao, M. J., Vonsattel, J. P. G., Pinto, R. M., Lucente, D., Abu-Elneel, K., Ramos, E. M., Mysore, J. S., Gillis, T., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.003 · Cited by 655
Björkqvist, M., Wild, E. J., Thiele, J., Silvestroni, A., Andre, R., Lahiri, N., Raibon, E., Lee, R. V., Benn, C. L., Soulet, D., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080178 · Cited by 650 · cited 2×
“…mitochondrial fragmentation in microglial cells leads to a proinflammatory state in the brain vasculature (Ferger et al., 2010), and activated microglial cells (Park et al., 2013) and several HD mouse models as well as HD patients have increased plasma cytokine levels (Björkqvist et al., 2008).”
BackgroundSelf-citationHughes, R. N. (2004) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.06.006 · Cited by 641 · cited 1×
“The percentage of spontaneous alternation was calculated (Drew et al., 1973; Hughes, 2004).”
MethodSong, W., Chen, J., Petrilli, A., Liot, G., Klinglmayr, E., Zhou, Y., Poquiz, P., Tjong, J., Pouladi, M. A., Hayden, M. R., et al. (2011) · Nature Medicine · doi:10.1038/nm.2313 · Cited by 555
Nakahira, K., Kyung, S.-Y., Rogers, A. J., Gazourian, L., Youn, S., Massaro, A. F., Quintana, C., Osorio, J. C., Wang, Z., Zhao, Y., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001577 · Cited by 445 · cited 4×
“We focused on biomarkers related to (a) mitochondrial and cell integrity (measuring mtDNA in the plasma; Chiu et al., 2003; Xia et al., 2009b; Nakahira et al., 2013), (b) mtHtt aggregation in the peripheral tissue (Sathasivam et al.”
BackgroundMethodInfluentialNovel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity
Qi, X., Qvit, N., Su, Y.-C., & Mochly-Rosen, D. (2012) · Journal of Cell Science · doi:10.1242/jcs.114439 · Cited by 439
Self-citationGenome-wide expression profiling of human blood reveals biomarkers for Huntington's disease
Borovecki, F., Lovrecic, L., Zhou, J., Jeong, H., Then, F., Rosas, H. D., Hersch, S. M., Hogarth, P., Bouzou, B., Jensen, R. V., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504921102 · Cited by 414
Energy metabolism defects in Huntington's disease and effects of coenzyme Q10
Koroshetz, W. J., Jenkins, B. G., Rosen, B. R., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410206 · Cited by 405 · cited 2×
“Moreover, clinical evidence shows that metabolic impairment precedes neuropathology and clinical symptoms in HD patients (Koroshetz et al., 1997; Feigin et al., 2001; Ciarmiello et al., 2006; Powers et al., 2007), indicating that mitochondrial dysfunction and metabolic deficit are early events in…”
BackgroundGuo, X., Disatnik, M.-H., Monbureau, M., Shamloo, M., Mochly-Rosen, D., & Qi, X. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70911 · Cited by 370 · cited 26×
“…impairment by a novel Drp1/Fis1 peptide inhibitor, P110 (Qi et al., 2013), rescued mtHtt-induced mitochondrial injury, corrected defects in mitochondrial function, and reduced neuronal cell death both in HD patient–derived neuronal cultures and in HD transgenic mouse brains (Guo et al., 2013).”
BackgroundMethodInfluentialSelf-citationMitochondrial loss, dysfunction and altered dynamics in Huntington's disease
Kim, J., Moody, J. P., Edgerly, C. K., Bordiuk, O. L., Cormier, K., Smith, K., Beal, M. F., & Ferrante, R. J. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq306 · Cited by 357 · cited 2×
“Collectively, these results show that the highest increase in mtDNA in the plasma preceded maximal behavioral deficits of R6/2 mice, consistent with the evidence that mitochondrial damage occurred at the early stage of HD (Kim et al., 2010).”
BackgroundResultDisatnik, M., Ferreira, J. C. B., Campos, J. C., Gomes, K. S., Dourado, P. M. M., Qi, X., & Mochly‐Rosen, D. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000461 · Cited by 334 · cited 2×
“We showed that P110 inhibits excessive mitochondrial fission in several models of neurodegenerative disease as well as in a rat heart model of ischemia/reperfusion injury, without affecting basal (physiological) fission (Disatnik et al., 2013; Guo et al., 2013; Qi et al., 2013).”
BackgroundSelf-citationMutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors
Crotti, A., Benner, C., Kerman, B. E., Gosselin, D., Lagier-Tourenne, C., Zuccato, C., Cattaneo, E., Gage, F. H., Cleveland, D. W., & Glass, C. K. (2014) · Nature Neuroscience · doi:10.1038/nn.3668 · Cited by 333 · cited 1×
“Inflammation is due, in part, to activation of microglia and recruitment of astrocytes associated with mtHtt, which leads to enhanced secretion of cytokines and chemokines by microglia (Crotti et al., 2014).”
Background(2010) · Frontiers in neuroscience · doi:10.1201/crcfroneusci · Cited by 322
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG
Hersch, S. M., Gevorkian, S., Marder, K., Moskowitz, C., Feigin, A., Cox, M., Como, P., Zimmerman, C., Lin, M., Zhang, L., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000194318.74946.b6 · Cited by 313 · cited 1×
“Our data are also consistent with five of six other patient sample analyses (Browne et al., 1997; Polidori et al., 1999; Hersch et al., 2006; Chen et al., 2007; Long et al., 2012; Ciancarelli et al., 2014).”
ResultFormation of Polyglutamine Inclusions in Non-CNS Tissue
Sathasivam, K., Hobbs, C., Turmaine, M., Mangiarini, L., Mahal, A., Bertaux, F., Wanker, E. E., Doherty, P., Davies, S. W., & Bates, G. P. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.5.813 · Cited by 289 · cited 7×
“How- 2659JEM Vol. 213, No. 12 ever, non–central nervous system (non-CNS) tissues of the HD mice model also have mtHtt aggregates as well as evidence of oxidative stress (Sathasivam et al., 1999).”
BackgroundInfluentialPolyglutamine diseases: emerging concepts in pathogenesis and therapy
Shao, J., & Diamond, M. I. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm213 · Cited by 287
The choreography of neuroinflammation in Huntington's disease
Crotti, A., & Glass, C. K. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.04.007 · Cited by 276 · cited 3×
“P110 treatment decreases the levels of inflammatory markers in plasma of Hd mice Activated monocytes are observed in presymptomatic HD patients (Crotti and Glass, 2015), and inflammation triggered by the presence of mtHtt was reported in mouse models of HD and in HD patients (Hsiao et al.”
BackgroundMitochondrial dynamics modulate the expression of pro‐inflammatory mediators in microglial cells
Park, J., Choi, H., Min, J., Park, S., Kim, J., Park, H., Kim, B., Chae, J., Yim, M., & Lee, D. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12361 · Cited by 274 · cited 2×
“…mitochondrial fragmentation in microglial cells leads to a proinflammatory state in the brain vasculature (Ferger et al., 2010), and activated microglial cells (Park et al., 2013) and several HD mouse models as well as HD patients have increased plasma cytokine levels (Björkqvist et al., 2008).”
BackgroundSelinummi, J., Seppälä, J., Yli-Harja, O., & Puhakka, J. A. (2005) · BioTechniques · doi:10.2144/000112018 · Cited by 263 · cited 2×
“10 respective staining were separated from background pixels producing a binarized image (Selinummi et al., 2005).”
BackgroundMethodIncreased oxidative damage to DNA in a transgenic mouse model of Huntington's disease
Bogdanov, M. B., Andreassen, O. A., Dedeoglu, A., Ferrante, R. J., & Beal, M. F. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00689.x · Cited by 248 · cited 3×
“…there are conflicting studies on the use of 8-OHdG as an oxidative stress marker: urine and plasma from R6/2 mice were found to have high levels of 8-OHdG using high-performance liquid chromatography with an electrochemical detection analytic technique in a study (Bogdanov et al., 1999, 2001).”
BackgroundMethodResultInfluentialHsiao, H.-Y., Chen, Y.-C., Chen, H.-M., Tu, P.-H., & Chern, Y. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt036 · Cited by 239 · cited 2×
“P110 treatment decreases the levels of inflammatory markers in plasma of Hd mice Activated monocytes are observed in presymptomatic HD patients (Crotti and Glass, 2015), and inflammation triggered by the presence of mtHtt was reported in mouse models of HD and in HD patients (Hsiao et al., 2013; Crotti and Glass, 2015…”
BackgroundChen, C.-M., Wu, Y.-R., Cheng, M.-L., Liu, J.-L., Lee, Y.-M., Lee, P.-W., Soong, B.-W., & Chiu, D. T.-Y. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.05.093 · Cited by 228 · cited 1×
“Our data are also consistent with five of six other patient sample analyses (Browne et al., 1997; Polidori et al., 1999; Hersch et al., 2006; Chen et al., 2007; Long et al., 2012; Ciancarelli et al., 2014).”
ResultLow cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease
Podlesniy, P., Figueiro‐Silva, J., Llado, A., Antonell, A., Sanchez‐Valle, R., Alcolea, D., Lleo, A., Molinuevo, J. L., Serra, N., & Trullas, R. (2013) · Annals of Neurology · doi:10.1002/ana.23955 · Cited by 219
Kohler, C., Radpour, R., Barekati, Z., Asadollahi, R., Bitzer, J., Wight, E., Bürki, N., Diesch, C., Holzgreve, W., & Zhong, X. Y. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-105 · Cited by 215 · cited 2×
“, 2013) and for diseases such as cancer and neurodegenerative diseases (Kohler et al., 2009; Xia et al., 2009a; Podlesniy et al., 2013).”
Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex
Polidori, M. C., Mecocci, P., Browne, S. E., Senin, U., & Beal, M. F. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00578-9 · Cited by 211 · cited 1×
“Our data are also consistent with five of six other patient sample analyses (Browne et al., 1997; Polidori et al., 1999; Hersch et al., 2006; Chen et al., 2007; Long et al., 2012; Ciancarelli et al., 2014).”
ResultLi, J. Y., Popovic, N., & Brundin, P. (2005) · NeuroRX · doi:10.1602/neurorx.2.3.447 · Cited by 211 · cited 2×
“, 1993), there has been considerable effort toward developing therapeutic strategies for HD, and several compounds have shown beneficial effects in various HD cell and transgenic mouse models (Li et al., 2005; Ray and Shoulson, 2011; Guo et al., 2013).”
BackgroundQuantitative Analysis of Circulating Mitochondrial DNA in Plasma
Chiu, R. W. K., Chan, L. Y. S., Lam, N. Y. L., Tsui, N. B. Y., Ng, E. K. O., Rainer, T. H., & Lo, Y. M. D. (2003) · Clinical Chemistry · doi:10.1373/49.5.719 · Cited by 208 · cited 5×
“Plasma was obtained by a single centrifugation step at 1,600 g for 10 min, as previously reported (Chiu et al., 2003).”
BackgroundMethodInfluentialMetabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study.
Feigin, A., Leenders, K. L., Moeller, J. R., Missimer, J. H., Kuenig, G., Spetsieris, P. G., Antonini, A., & Eidelberg, D. (2001) · PubMed · Cited by 204
Bogdanov, M. B., Beal, M. F., McCabe, D. R., Griffin, R. M., & Matson, W. R. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00113-6 · Cited by 179 · cited 1×
“…there are conflicting studies on the use of 8-OHdG as an oxidative stress marker: urine and plasma from R6/2 mice were found to have high levels of 8-OHdG using high-performance liquid chromatography with an electrochemical detection analytic technique in a study (Bogdanov et al., 1999, 2001).”
MethodSelective defect of in vivo glycolysis in early Huntington's disease striatum
Powers, W. J., Videen, T. O., Markham, J., McGee-Minnich, L., Antenor-Dorsey, J. V., Hershey, T., & Perlmutter, J. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609833104 · Cited by 174 · cited 2×
“…clinical evidence shows that metabolic impairment precedes neuropathology and clinical symptoms in HD patients (Koroshetz et al., 1997; Feigin et al., 2001; Ciarmiello et al., 2006; Powers et al., 2007), indicating that mitochondrial dysfunction and metabolic deficit are early events in HD.”
BackgroundLee, J., Kosaras, B., Del Signore, S. J., Cormier, K., McKee, A., Ratan, R. R., Kowall, N. W., & Ryu, H. (2011) · Acta Neuropathologica · doi:10.1007/s00401-010-0788-5 · Cited by 168 · cited 2×
“7 JEM sured by increased aldehydic load in human and mice brain tissues (levels of 4-HNE adducts; Lee et al., 2011) and DNA damage (as measured by the presence of a product of DNA repair in the urine, 8-OHdG; Browne et al.”
BackgroundInfluentialOliveira, J. M. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06741.x · Cited by 163 · cited 2×
“, 2013) as a main contributor to neurodegeneration and is associated with the accumulation of mtHtt protein at the mitochondria and in the nucleus (Oliveira, 2010; Costa and Scorrano, 2012).”
BackgroundStaying cool in difficult times: Mitochondrial dynamics, quality control and the stress response
Shutt, T. E., & McBride, H. M. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.05.024 · Cited by 163 · cited 2×
“mtDNA may also reflect active exosome-mediated release of damaged mitochondria (Shutt and McBride, 2013).”
BackgroundDevelopment of biomarkers for Huntington's disease
Weir, D. W., Sturrock, A., & Leavitt, B. R. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70070-9 · Cited by 161 · cited 1×
“However, human trials in HD are time consuming because of the slow progression of the disease, its insidious onset, and patient-to-patient variability (MacDonald et al., 1993; Weir et al., 2011).”
BackgroundSelf-citationShaping the role of mitochondria in the pathogenesis of Huntington's disease
Costa, V., & Scorrano, L. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.65 · Cited by 161 · cited 4×
“The neurological symptoms of HD are caused by the aggregation of mtHtt protein in neurons that causes, among other pathologies, mitochondrial dysfunction (Shao and Diamond, 2007; Costa and Scorrano, 2012).”
BackgroundInfluentialPolitis, M., Lahiri, N., Niccolini, F., Su, P., Wu, K., Giannetti, P., Scahill, R. I., Turkheimer, F. E., Tabrizi, S. J., & Piccini, P. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.08.011 · Cited by 153 · cited 2×
“P110 treatment decreases the levels of inflammatory markers in plasma of Hd mice Activated monocytes are observed in presymptomatic HD patients (Crotti and Glass, 2015), and inflammation triggered by the presence of mtHtt was reported in mouse models of HD and in HD patients (Hsiao et al., 2013; Crotti and Glass, 2015…”
BackgroundImpaired GAPDH‐induced mitophagy contributes to the pathology of Huntington's disease
Hwang, S., Disatnik, M., & Mochly‐Rosen, D. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505256 · Cited by 153 · cited 1×
“This, in turn, leads to loss of ATP and increase in oxidative stress (Costa and Scorrano, 2012; Guo et al., 2013; Hwang et al., 2015).”
BackgroundSelf-citationModulation of nucleosome dynamics in Huntington's disease
Stack, E. C., Del Signore, S. J., Luthi-Carter, R., Soh, B. Y., Goldstein, D. R., Matson, S., Goodrich, S., Markey, A. L., Cormier, K., Hagerty, S. W., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm064 · Cited by 120 · cited 1×
“In contrast, our data using the ELI SA method on mouse urine samples are consistent with the studies by Bogdanov et al. (2001) and Stack et al. (2007) using urine of R6/2 and Q82 mice, respectively, showing a 2.5-fold increase in 8-OHdG in the urine of 13-wk-old R6/2 HD mice relative to age-matched…”
ResultInfluentialOxidative modification of lipoic acid by HNE in Alzheimer disease brain
Hardas, S. S., Sultana, R., Clark, A. M., Beckett, T. L., Szweda, L. I., Murphy, M. P., & Butterfield, D. A. (2013) · Redox Biology · doi:10.1016/j.redox.2013.01.002 · Cited by 120 · cited 1×
“Therefore, we determined the presence of mtHtt aggregates and 4-HNE adducts on proteins (an aldehydic product of lipid oxidation; Hardas et al., 2013) in skeletal muscle and skin of 13-wkold R6/2 mice.”
BackgroundEffects of mitochondrial dysfunction on the immunological properties of microglia
Ferger, A. I., Campanelli, L., Reimer, V., Muth, K. N., Merdian, I., Ludolph, A. C., & Witting, A. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-45 · Cited by 120 · cited 2×
“In addition, excessive mitochondrial fragmentation in microglial cells leads to a proinflammatory state in the brain vasculature (Ferger et al., 2010), and activated microglial cells (Park et al., 2013) and several HD mouse models as well as HD patients have increased plasma cytokine levels…”
BackgroundPlasma Mitochondrial DNA Concentrations after Trauma
Lam, N. Y. L., Rainer, T. H., Chiu, R. W. K., Joynt, G. M., & Lo, Y. M. D. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.025783 · Cited by 98 · cited 2×
“Quantification of nuclear and mtDNA raised great interest as a noninvasive diagnostic for patients after trauma (Lam et al., 2004; Nakahira et al., 2013) and for diseases such as cancer and neurodegenerative diseases (Kohler et al.”
BackgroundChen, C. (2011) · PubMed · Cited by 97
Decreased mitochondrial DNA content in blood samples of patients with stage I breast cancer
Xia, P., An, H.-X., Dang, C.-X., Radpour, R., Kohler, C., Fokas, E., Engenhart-Cabillic, R., Holzgreve, W., & Zhong, X. Y. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-454 · Cited by 94 · cited 4×
“, 2013) and for diseases such as cancer and neurodegenerative diseases (Kohler et al., 2009; Xia et al., 2009a; Podlesniy et al., 2013).”
BackgroundMethodInfluential8OHdG as a marker for Huntington disease progression
Long, J. D., Matson, W. R., Juhl, A. R., Leavitt, B. R., & Paulsen, J. S. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.02.012 · Cited by 71
Self-citationTräger, U., Andre, R., Magnusson-Lind, A., Miller, J. R. C., Connolly, C., Weiss, A., Grueninger, S., Silajdžić, E., Smith, D. L., Leavitt, B. R., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.10.012 · Cited by 63 · cited 2×
“P110 treatment decreases the levels of inflammatory markers in plasma of Hd mice Activated monocytes are observed in presymptomatic HD patients (Crotti and Glass, 2015), and inflammation triggered by the presence of mtHtt was reported in mouse models of HD and in HD patients (Hsiao et al., 2013; Crotti and Glass, 2015…”
BackgroundSelf-citationBudnik, L. T., Kloth, S., Baur, X., Preisser, A. M., & Schwarzenbach, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064413 · Cited by 60 · cited 2×
“1 A. GAP DH, a nuclear gene, was used as a control (Xia et al., 2009a,b; Budnik et al., 2013).”
MethodEffects of ?9-THC, LSD-25 and scopolamine on continuous, spontaneous alternation in the Y-maze
Drew, W. G., Miller, L. L., & Baugh, E. L. (1973) · Psychopharmacology · doi:10.1007/bf00428688 · Cited by 56 · cited 1×
“The percentage of spontaneous alternation was calculated (Drew et al., 1973; Hughes, 2004).”
MethodMetabolism in HD: Still a relevant mechanism?
Duan, W., Jiang, M., & Jin, J. (2014) · Movement Disorders · doi:10.1002/mds.25992 · Cited by 41 · cited 2×
“2 impaired mitochondrial dysfunction has been shown in some cases to be a beneficial strategy to delay HD onset and to slow disease progression after its onset (Duan et al., 2014).”
BackgroundXia, P., Radpour, R., Zachariah, R., Fan, A. X. C., Kohler, C., Hahn, S., Holzgreve, W., & Zhong, X. Y. (2009) · Genetics and Molecular Biology · doi:10.1590/s1415-47572009000100003 · Cited by 34 · cited 4×
“We focused on biomarkers related to (a) mitochondrial and cell integrity (measuring mtDNA in the plasma; Chiu et al., 2003; Xia et al., 2009b; Nakahira et al., 2013), (b) mtHtt aggregation in the peripheral tissue (Sathasivam et al.”
BackgroundMethodInfluentialCiancarelli, I., Amicis, D. D., Massimo, C. D., Scanno, C. D., Pistarini, C., D’Orazio, N., & Ciancarelli, M. G. T. (2014) · Biomarkers · doi:10.3109/1354750x.2014.935955 · Cited by 26 · cited 1×
“Our data are also consistent with five of six other patient sample analyses (Browne et al., 1997; Polidori et al., 1999; Hersch et al., 2006; Chen et al., 2007; Long et al., 2012; Ciancarelli et al., 2014).”
Result8OHdG is not a biomarker for Huntington disease state or progression
Borowsky, B., Warner, J., Leavitt, B. R., Tabrizi, S. J., Roos, R. A. C., Durr, A., Becker, C., Sampaio, C., Tobin, A. J., & Schulman, H. (2013) · Neurology · doi:10.1212/wnl.0b013e318293e1a1 · Cited by 26 · cited 1×
“In a careful study on cohorts of presymptomatic and symptomatic HD patients (32 each), Borowsky et al. (2013) reported that plasma 8-OHdG was not found to be a biomarker of disease progression when using either liquid chromatography–mass spectrometry assay or liquid chromatography–electrochemical…”
MethodSelf-citationBiomarker development for Huntington's disease
André, R., Scahill, R. I., Salman, H., & Tabrizi, S. J. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.03.002 · Cited by 24 · cited 1×
“Andre et al. (2014) evaluated in detail the advantages and disadvantages of several biomarkers used to follow HD patients.”
BackgroundReducing the risk of failure: biomarker-guided trial design
Townsend, M. J., & Arron, J. R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.124 · Cited by 21
The challenge in translating basic research discoveries to treatment of Huntington disease
Mochly‐Rosen, D., Disatnik, M., & Qi, X. (2014) · Rare Diseases · doi:10.4161/rdis.28637 · Cited by 11 · cited 2×
“Multiple models of HD have been developed, and R6/2 mice exhibit a fast progression of the disease, whereas YAC128 mice and other models show slower disease progression (Mochly-Rosen et al., 2014).”
BackgroundSelf-citationHuntington’s Disease: Clinical Experimental Therapeutics
Ray, D. E., & Shoulson, I. (2011) · Cited by 3
(2006) · PubMed
Cited by
Joshi, A. U., Minhas, P. S., Liddelow, S. A., Haileselassie, B., Andreasson, K. I., Dorn, G. W., & Mochly-Rosen, D. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0486-0 · Cited by 571
Self-citationEvolving and Expanding the Roles of Mitophagy as a Homeostatic and Pathogenic Process
Gustafsson, Å. B., & Dorn, G. W. (2019) · Physiological Reviews · doi:10.1152/physrev.00005.2018 · Cited by 228
Haileselassie, B., Joshi, A. U., Minhas, P. S., Mukherjee, R., Andreasson, K. I., & Mochly-Rosen, D. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1689-8 · Cited by 203
Self-citationInhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis
Joshi, A. U., Saw, N. L., Vogel, H., Cunnigham, A. D., Shamloo, M., & Mochly‐Rosen, D. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708166 · Cited by 180
“…of mitochondria with damaged cristae (P = 0.0086). mtDNA content has been previously used to assess the mitochondrial number in various diseases, including ALS, where a significant decrease was observed in the spinal cord of patients (Wiedemann et al, 2002; Kim et al, 2010; Disatnik et al, 2016).”
MethodSelf-citationJoshi, A. U., Saw, N. L., Shamloo, M., & Mochly-Rosen, D. (2018) · Oncotarget · doi:10.18632/oncotarget.23640 · Cited by 145
“The animals used in the P110 treatment study were implanted with a 28 days osmotic pump (Alzet) containing TAT47–57 carrier control peptide or P110-TAT47–57, which delivered to the mice at a rate of 3 mg/Kg/day, as described previously [67].”
MethodSelf-citation
Metadata
- Authors
- Disatnik, M.-H., Joshi, A. U., Saw, N. L., Shamloo, M., Leavitt, B. R., Qi, X., & Mochly-Rosen, D.
- Affiliations
- Stanford Medicine (US)
- University of British Columbia (CA)
- Case Western Reserve University (US)
- Department of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, CA 94305 1
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2016-11-07
- Volume
- 213
- Issue
- 12
- Pages
- 2655-2669
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC5110026
- OpenAlex
- W2554473742
- Cited by
- 58
- References
- 69
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 4 · 2023: 5 · 2022: 9 · 2021: 6 · 2020: 6 · 2019: 5 · 2018: 11 · 2017: 2
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (HL52141)
- TAKEDA Pharmaceuticals U.S.A.
- NIH (R01 NS088192)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- Huntington's disease, peripheral biomarkers, disease progression, treatment response, p110, mitochondrial fragmentation, mitochondrial DNA, oxidative DNA damage, 4-hydroxynonenal, mutant huntingtin aggregates, neuroinflammation, R6/2 mice, plasma biomarkers, clinical trial endpoints
- MeSH terms
- Aldehydes, Animals, Behavior, Animal, Body Fluids, Brain, DNA Damage, DNA, Mitochondrial, Humans, Huntington Disease, Inflammation, Mitochondria, Oxidation-Reduction, Phenotype, Biomarkers, Case-Control Studies, Disease Progression, Muscle, Skeletal, Mice, Protein Aggregates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.